HDAC9 and pulmonary arterial hypertension: Finally, the identification of dysregulated HDAC isoforms in PAH, and their transcriptional targets (Supplementary Fig. 2E) have paved a way to specifically target the acetylation pathway using isoform-selective HDAC inhibitors ex vivo and in vivo.